dihydropyridine receptor

WordNet

1. a cellular structure that is postulated to exist in order to mediate between a chemical agent that acts on nervous tissue and the physiological response

PrepTutorEJDIC

1. =sense organ / 受信装置

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2012/05/28 20:24:21」(JST)

wiki en

[Wiki en表示]

Calcium channel, voltage-dependent, L type, alpha 1S subunit
Available structures PDB Ortholog search: PDBe, RCSB List of PDB id codes 2VAY
Identifiers
Symbols	CACNA1S; CACNL1A3; CCHL1A3; Cav1.1; HOKPP; HOKPP1; MHS5; TTPP1; hypoPP
External IDs	OMIM: 114208 MGI: 88294 HomoloGene: 37257 IUPHAR: Cav1.1 ChEMBL: 3805 GeneCards: CACNA1S Gene
Gene Ontology Molecular function • voltage-gated ion channel activity • voltage-gated calcium channel activity • high voltage-gated calcium channel activity Cellular component • cytoplasm • plasma membrane • voltage-gated calcium channel complex • integral to membrane • sarcoplasmic reticulum • T-tubule • I band Biological process • skeletal system development • extraocular skeletal muscle development • ion transport • calcium ion transport • muscle contraction • striated muscle contraction • endoplasmic reticulum organization • axon guidance • myoblast fusion • neuromuscular junction development • skeletal muscle adaptation • regulation of calcium ion transport via voltage-gated calcium channel activity • muscle cell development • transmembrane transport Sources: Amigo / QuickGO
RNA expression pattern
More reference expression data
Orthologs
Species	Human	Mouse
Entrez	779	12292
Ensembl	ENSG00000081248	ENSMUSG00000026407
UniProt	Q13698	A3KPC9
RefSeq (mRNA)	NM_000069.2	NM_001081023.1
RefSeq (protein)	NP_000060.2	NP_001074492.1
Location (UCSC)	Chr 1: 201.01 – 201.08 Mb	Chr 1: 137.95 – 138.02 Mb
PubMed search	[1]	[2]

Ca_v1.1 also known as the calcium channel, voltage-dependent, L type, alpha 1S subunit, (CACNA1S), is a protein which in humans is encoded by the CACNA1S gene. It is also known as CACNL1A3 and the dihydropyridine receptor (DHPR).

Function

This gene encodes one of the five subunits of the slowly inactivating L-type voltage-dependent calcium channel in skeletal muscle cells. Mutations in this gene have been associated with hypokalemic periodic paralysis, thyrotoxic periodic paralysis and malignant hyperthermia susceptibility.

Ca_v1.1 is a voltage-dependent calcium channel found in the transverse tubule of muscles. In skeletal muscle it associates with the ryanodine receptor RyR1 of the sarcoplasmic reticulum via a mechanical linkage. It senses the voltage change caused by the end-plate potential from nervous stimulation and propagated by sodium channels as action potentials to the T-tubules. It was previously thought that when the muscle depolarises, the calcium channel opens, allowing calcium in and activating RyR1, which mediates much greater calcium release from the sarcoplasmic reticulum. This is the first part of the process of excitation-contraction coupling, which ultimately causes the muscle to contract. Recent findings suggest that in skeletal muscle (but not heart muscle), calcium entry through Cav1.1 is not required; Cav1.1 undergoes a conformational change which allosterically activates RyR1.

Clinical significance

In hypokalemic periodic paralysis (HOKPP), the voltage sensors in domains 2 and 4 of Ca_v1.1 are mutated (loss-of-function), reducing the availability of the channel to sense depolarisation, and therefore it cannot activate the ryanodine receptor as efficiently. As a result, the muscle cannot contract very well and the patient is paralysed. The condition is hypokalemic because a low extracellular potassium ion concentration will cause the muscle to repolarise to the resting potential more quickly, so any calcium conductance that does occur cannot be sustained. It becomes more difficult to reach the threshold at which the muscle can contract, and even if this is reached then the muscle is more prone to relaxing. Because of this, the severity would be reduced if potassium ion concentrations are maintained. In contrast, hyperkalemic periodic paralysis refers to gain-of-function mutations in sodium channels that maintain muscle depolarisation and therefore are aggravated by high potassium ion concentrations.

Blockers

Ca_v1.1 is blocked by dihydropyridine.

See also

• Calcium channel

References

Further reading

• Catterall WA, Perez-Reyes E, Snutch TP, Striessnig J (2006). "International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels". Pharmacol. Rev. 57 (4): 411–25. doi:10.1124/pr.57.4.5. PMID 16382099. 
• Rotman EI, De Jongh KS, Florio V, et al. (1992). "Specific phosphorylation of a COOH-terminal site on the full-length form of the alpha 1 subunit of the skeletal muscle calcium channel by cAMP-dependent protein kinase". J. Biol. Chem. 267 (23): 16100–5. PMID 1322891. 
• Röhrkasten A, Meyer HE, Nastainczyk W, et al. (1988). "cAMP-dependent protein kinase rapidly phosphorylates serine- 687 of the skeletal muscle receptor for calcium channel blockers". J. Biol. Chem. 263 (30): 15325–9. PMID 2844809. 
• Tanabe T, Takeshima H, Mikami A, et al. (1987). "Primary structure of the receptor for calcium channel blockers from skeletal muscle". Nature 328 (6128): 313–8. doi:10.1038/328313a0. PMID 3037387. 
• Hogan K, Powers PA, Gregg RG (1995). "Cloning of the human skeletal muscle alpha 1 subunit of the dihydropyridine-sensitive L-type calcium channel (CACNL1A3)". Genomics 24 (3): 608–9. doi:10.1006/geno.1994.1677. PMID 7713519. 
• Elbaz A, Vale-Santos J, Jurkat-Rott K, et al. (1995). "Hypokalemic periodic paralysis and the dihydropyridine receptor (CACNL1A3): genotype/phenotype correlations for two predominant mutations and evidence for the absence of a founder effect in 16 caucasian families". Am. J. Hum. Genet. 56 (2): 374–80. PMC 1801148. PMID 7847370. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1801148. 
• Boerman RH, Ophoff RA, Links TP, et al. (1995). "Mutation in DHP receptor alpha 1 subunit (CACLN1A3) gene in a Dutch family with hypokalaemic periodic paralysis". J. Med. Genet. 32 (1): 44–7. doi:10.1136/jmg.32.1.44. PMC 1050178. PMID 7897626. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1050178. 
• Gregg RG, Couch F, Hogan K, Powers PA (1993). "Assignment of the human gene for the alpha 1 subunit of the skeletal muscle DHP-sensitive Ca2+ channel (CACNL1A3) to chromosome 1q31-q32". Genomics 15 (1): 107–12. doi:10.1006/geno.1993.1017. PMID 7916735. 
• Jurkat-Rott K, Lehmann-Horn F, Elbaz A, et al. (1995). "A calcium channel mutation causing hypokalemic periodic paralysis". Hum. Mol. Genet. 3 (8): 1415–9. doi:10.1093/hmg/3.8.1415. PMID 7987325. 
• Ptácek LJ, Tawil R, Griggs RC, et al. (1994). "Dihydropyridine receptor mutations cause hypokalemic periodic paralysis". Cell 77 (6): 863–8. doi:10.1016/0092-8674(94)90135-X. PMID 8004673. 
• Drouet B, Garcia L, Simon-Chazottes D, et al. (1994). "The gene coding for the alpha 1 subunit of the skeletal dihydropyridine receptor (Cchl1a3 = mdg) maps to mouse chromosome 1 and human 1q32". Mamm. Genome 4 (9): 499–503. doi:10.1007/BF00364784. PMID 8118099. 
• Iles DE, Segers B, Olde Weghuis D, et al. (1994). "Refined localization of the alpha 1-subunit of the skeletal muscle L-type voltage-dependent calcium channel (CACNL1A3) to human chromosome 1q32 by in situ hybridization". Genomics 19 (3): 561–3. doi:10.1006/geno.1994.1106. PMID 8188298. 
• O'Brien RO, Taske NL, Hansbro PM, et al. (1996). "Exclusion of defects in the skeletal muscle specific regions of the DHPR alpha 1 subunit as frequent causes of malignant hyperthermia". J. Med. Genet. 32 (11): 913–4. doi:10.1136/jmg.32.11.913. PMC 1051750. PMID 8592342. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1051750. 
• Hogan K, Gregg RG, Powers PA (1997). "The structure of the gene encoding the human skeletal muscle alpha 1 subunit of the dihydropyridine-sensitive L-type calcium channel (CACNL1A3)". Genomics 31 (3): 392–4. doi:10.1006/geno.1996.0066. PMID 8838325. 
• Robinson RL, Monnier N, Wolz W, et al. (1997). "A genome wide search for susceptibility loci in three European malignant hyperthermia pedigrees". Hum. Mol. Genet. 6 (6): 953–61. doi:10.1093/hmg/6.6.953. PMID 9175745. 
• Monnier N, Procaccio V, Stieglitz P, Lunardi J (1997). "Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle". Am. J. Hum. Genet. 60 (6): 1316–25. doi:10.1086/515454. PMC 1716149. PMID 9199552. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1716149. 
• Meyers MB, Puri TS, Chien AJ, et al. (1998). "Sorcin associates with the pore-forming subunit of voltage-dependent L-type Ca2+ channels". J. Biol. Chem. 273 (30): 18930–5. doi:10.1074/jbc.273.30.18930. PMID 9668070. 
• Morrill JA, Brown RH, Cannon SC (1999). "Gating of the L-type Ca channel in human skeletal myotubes: an activation defect caused by the hypokalemic periodic paralysis mutation R528H". J. Neurosci. 18 (24): 10320–34. PMID 9852570. 
• Protasi F, Paolini C, Nakai J, et al. (2003). "Multiple regions of RyR1 mediate functional and structural interactions with alpha(1S)-dihydropyridine receptors in skeletal muscle". Biophys. J. 83 (6): 3230–44. doi:10.1016/S0006-3495(02)75325-3. PMC 1302400. PMID 12496092. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1302400. 
• Carsana A, Fortunato G, De Sarno C, et al. (2003). "Identification of new polymorphisms in the CACNA1S gene". Clin. Chem. Lab. Med. 41 (1): 20–2. doi:10.1515/CCLM.2003.004. PMID 12636044. 

}}

External links

• GeneReviews/NCBI/NIH/UW entry on Malignant Hyperthermia Susceptibility
• MeSH CACNA1S+protein,+human

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. 原発性（本態性）高血圧における薬物療法の選択：推奨 choice of drug therapy in primary essential hypertension recommendations
• 2. 糖尿病患者における高血圧治療 treatment of hypertension in patients with diabetes mellitus
• 3. 急性および慢性腎臓病における高血圧の概要 overview of hypertension in acute and chronic kidney disease
• 4. 成人の非糖尿病性慢性腎臓病患者に対する降圧療法と病状の進展 antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults
• 5. 動脈瘤性くも膜下出血の治療 treatment of aneurysmal subarachnoid hemorrhage

English Journal

• Sympathetic denervation facilitates L-type Ca2+ channel activation in renal but not in mesenteric resistance arteries.

• Heumann P1, Koenen A, Zavaritskaya O, Schütze K, Ramm A, Schlüter T, Steinbach A, Rettig R, Schubert R, Grisk O.
• Journal of hypertension.J Hypertens.2016 Apr;34(4):692-703. doi: 10.1097/HJH.0000000000000856.
• OBJECTIVES: Sympathetic denervation enhances agonist-induced vasoconstriction. This effect may involve altered function of signaling mechanisms such as Rho kinase (Rock) and L-type Ca channels downstream from vasoconstrictor receptors. We tested if enhanced Rock and L-type calcium channel activation
• PMID 26841239

• Thapsigargin-induced activation of Ca(2+)-CaMKII-ERK in brainstem contributes to substance P release and induction of emesis in the least shrew.

• Zhong W1, Chebolu S1, Darmani NA2.
• Neuropharmacology.Neuropharmacology.2016 Apr;103:195-210. doi: 10.1016/j.neuropharm.2015.11.023. Epub 2015 Nov 26.
• Cytoplasmic calcium (Ca(2+)) mobilization has been proposed to be an important factor in the induction of emesis. The selective sarcoplasmic/endoplasmic reticulum Ca(2+)-ATPase (SERCA) inhibitor thapsigargin, is known to deplete intracellular Ca(2+) stores, which consequently evokes extracellular Ca
• PMID 26631534

• Population Density and Moment-based Approaches to Modeling Domain Calcium-mediated Inactivation of L-type Calcium Channels.

• Wang X1, Hardcastle K1, Weinberg SH1, Smith GD2.
• Acta biotheoretica.Acta Biotheor.2016 Mar;64(1):11-32. doi: 10.1007/s10441-015-9271-y. Epub 2015 Sep 30.
• We present a population density and moment-based description of the stochastic dynamics of domain [Formula: see text]-mediated inactivation of L-type [Formula: see text] channels. Our approach accounts for the effect of heterogeneity of local [Formula: see text] signals on whole cell [Formula: see t
• PMID 26424585

Japanese Journal

• Dysferlin and Animal Models for Dysferlinopathy

• Kobayashi Kinji,Izawa Takeshi,Kuwamura Mitsuru,Yamate Jyoji
• Journal of Toxicologic Pathology 25(2), 135-147, 2012
• … It interacts with mitsugumin 53, annexins, caveolin-3, AHNAK, affixin, S100A10, calpain-3, tubulin and dihydropyridine receptor. …
• NAID 130001884601

• Establishment of a Stable Human Cell Line, HPL-A3, for Use in Reporter Gene Assays of Cytochrome P450 3A Inducers

• Sekimoto Masashi,Sano Shinsuke,Hosaka Takuomi,Nemoto Kiyomitsu,Degawa Masakuni
• Biological and Pharmaceutical Bulletin 35(5), 677-685, 2012
• … We have established a stable human cell line, termed HPL-A3, by co-transfection of a human pregnane X receptor (hPXR) expression vector and a reporter plasmid (p3A4-hPXRE-Luc) containing a luciferase gene and a promoter/enhancer region of the human cytochrome P450 3A4 (CYP3A4) gene into a human hepatoma-derived cell line, HepG2. … In addition, the induction of CALUX by dihydropyridine calcium channel blockers, which are known to act as CYP3A inducers in rats, was observed in HPL-A3 cells. …
• NAID 130001872224

Related Links

• Dihydropyridine Receptor alpha-1 Antibody Monoclonal (1A ...

Monoclonal Antibody against Dihydropyridine Receptor alpha-1 for use in Western Blot, Immunohistochemistry (Frozen), Immunohistochemistry (Paraffin), Flow Cytometry, Immunoprecipitation (MA3-920) ... General Information ...

• The Dihydropyridine Receptors - Springer

The purpose of this chapter is to review some of the recent studies on the characterization of 1,4-dihydropyridine receptors (DHPRs). In this respect the chapter will complement the contributions of G

Related Pictures

---

★リンクテーブル★

リンク元	「ジヒドロピリジン受容体」「ジヒドロピリジンレセプター」
拡張検索	「skeletal muscle dihydropyridine receptor gene」「skeletal muscle dihydropyridine receptor」
関連記事	「dihydropyridine」

「ジヒドロピリジン受容体」

　　[★]

英

dihydropyridine receptor, DHPR

関

カルシウムチャネル

PT. 284

「ジヒドロピリジンレセプター」

　　[★]

英

dihydropyridine receptor

関

ジヒドロピリジン受容体

「skeletal muscle dihydropyridine receptor gene」

　　[★] 骨格筋ジヒドロピリジン受容体遺伝子

「skeletal muscle dihydropyridine receptor」

　　[★] 骨格筋ジヒドロピリジン受容体

「dihydropyridine」

　　[★] ジヒドロピリジン DHP